TerminatedPhase 2

GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)

Stopped: No longer enrolling

United States184 participantsStarted 2020-06-10

Plain-language summary

This clinical trial will evaluate the safety, tolerability and effectiveness of topical GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18 or older * Able to provide informed consent * Able and willing to comply with study procedures * Able and willing to utilize an approved form of pregnancy prevention for women of child bearing potential through to the end of treatment Exclusion Criteria: * Know allergy to quinine, quinidine, or mefloquine * Confirmed prior positive test for SARS-CoV-2 * Treatment within the past 2 weeks with chloroquine, hydroxychloroquine, or remdesivir * Pregnancy or documentation of pregnancy by pre-treatment urine test or breast feeding or plans to become pregnant during the course of the study

What they're measuring

Number Serious Adverse Events as Assessed by CTCAE v5.0

Timeframe: Through 4 weeks of treatment

Incidence of SARS-CoV-2 Infection, Confirmed by PCR Relative to Treatment Group

Timeframe: Through 4 weeks of treatment

Trial details

NCT IDNCT04408183

SponsorGeneOne Life Science, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-01-10

Results submitted2025-07-15

View on ClinicalTrials.gov More SARS-CoV 2 trials